XBiotech (XBIT) Debt Ratio (2024)
XBiotech (XBIT) posted Debt Ratio of 0.05 for Q4 2024, up 5.4% on a QoQ basis from 0.05 in Q3 2024.
Powered by 
Analysis
XBiotech (XBIT) Debt Ratio (2024) Analysis & Trends
XBiotech has reported Debt Ratio for 1 years, with the latest figure at 0.05 in Q4 2024.
- On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.05 in Q4 2024; TTM through Dec 2024 was 0.05, a N/A change from a year earlier, with the FY2024 full-year figure at 0.05, changed N/A from the prior year.
- Debt Ratio was 0.05 for Q4 2024 at XBiotech, up from 0.05 in the prior quarter.
- The five-year high for Debt Ratio was 0.05 in Q4 2024, with the low at 0.04 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 0.66 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 0.05 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 0.05 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 0.25 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | XBiotech | 66.16 Mn | 66.16 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 0.05 |
| Sep 30, 2024 | 0.05 |
| Jun 30, 2024 | 0.05 |
| Mar 31, 2024 | 0.04 |